Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mengke Niu

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Molecular Cancer|September 26, 2022
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapyYuze Wu, Ming Yi, Mengke Niu, et al.
Cell Communication and Signaling : CCS|March 13, 2024
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signalingTianye Li, Mengke Niu, Jianwei Zhou, et al.
Annals of Translational Medicine|September 21, 2020
Upregulation of STAT1-CCL5 axis is a biomarker of colon cancer and promotes the proliferation of colon cancer cellsMengke Niu, Ming Yi, Bing Dong, et al.
Journal of Hematology & Oncology|January 8, 2021
Regulation of PD-L1 expression in the tumor microenvironmentMing Yi, Mengke Niu, Linping Xu, et al.
Experimental Hematology & Oncology|December 11, 2020
CD44 as a tumor biomarker and therapeutic targetHanxiao Xu, Mengke Niu, Xun Yuan, et al.
Frontiers in Oncology|August 12, 2021
Advances of Targeted Therapy for Hepatocellular CarcinomaMengke Niu, Ming Yi, Ning Li, et al.
Frontiers in Immunology|April 7, 2022
Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in CancerMengke Niu, Yiming Liu, Ming Yi, et al.
Experimental Hematology & Oncology|March 3, 2021
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLCMengke Niu, Ming Yi, Ning Li, et al.
Cancer Communications (London, England)|June 5, 2024
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumorsYuze Wu, Ming Yi, Mengke Niu, et al.
Molecular Cancer|January 22, 2022
Combination strategies with PD-1/PD-L1 blockade: current advances and future directionsMing Yi, Xiaoli Zheng, Mengke Niu, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Molecular Cancer|September 26, 2022
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapyYuze Wu, Ming Yi, Mengke Niu, et al.
Cell Communication and Signaling : CCS|March 13, 2024
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signalingTianye Li, Mengke Niu, Jianwei Zhou, et al.
Annals of Translational Medicine|September 21, 2020
Upregulation of STAT1-CCL5 axis is a biomarker of colon cancer and promotes the proliferation of colon cancer cellsMengke Niu, Ming Yi, Bing Dong, et al.
Journal of Hematology & Oncology|January 8, 2021
Regulation of PD-L1 expression in the tumor microenvironmentMing Yi, Mengke Niu, Linping Xu, et al.
Experimental Hematology & Oncology|December 11, 2020
CD44 as a tumor biomarker and therapeutic targetHanxiao Xu, Mengke Niu, Xun Yuan, et al.
Frontiers in Oncology|August 12, 2021
Advances of Targeted Therapy for Hepatocellular CarcinomaMengke Niu, Ming Yi, Ning Li, et al.
Frontiers in Immunology|April 7, 2022
Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in CancerMengke Niu, Yiming Liu, Ming Yi, et al.
Experimental Hematology & Oncology|March 3, 2021
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLCMengke Niu, Ming Yi, Ning Li, et al.
Cancer Communications (London, England)|June 5, 2024
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumorsYuze Wu, Ming Yi, Mengke Niu, et al.
Molecular Cancer|January 22, 2022
Combination strategies with PD-1/PD-L1 blockade: current advances and future directionsMing Yi, Xiaoli Zheng, Mengke Niu, et al.
Pageof 4